
Align Technology, Inc. (ALGN)
$
172
-0.79 (-0.46%)
Key metrics
Financial statements
Free cash flow per share
7.8289
Market cap
12.3 Billion
Price to sales ratio
3.0988
Debt to equity
0.0306
Current ratio
1.2887
Income quality
4.0865
Average inventory
236 Million
ROE
0.0975
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Align Technology, Inc. is a prominent medical device company known for designing, manufacturing, and marketing Invisalign clear aligners and iTero intraoral scanners, along with related services tailored for orthodontists, general practitioner dentists, and professionals involved in restorative and aesthetic dentistry. The company earned an interest income of $20,218,000.00 showcasing its financial investments. Additionally, it incurred an income tax expense of $187,597,000.00 indicating its tax obligations. With an operating income ratio of 0.15 the firm demonstrates its operational profitability margins. The gross profit stands at $2,799,159,000.00 highlighting the company's profitability from core operations, while the weighted average number of diluted shares outstanding is 74,993,000.00 reflecting potential dilution effects. Operating through two main segments—the Clear Aligner segment, which provides a range of treatment options for teenagers and younger patients, and the Scanners and Services segment, which offers advanced scanning solutions—the company serves a wide market that includes the United States, Switzerland, China, and beyond. The stock is priced at $131.39 positioning it in the higher-end market, with an average trading volume of 1,316,801.00 indicating moderate liquidity. Holding a mid-range market capitalization of $12,341,211,732.00 Align Technology, Inc. is recognized as a steady performer in the medical technology field. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. The diverse product offerings and reliable financial performance underscore Align Technology’s pivotal role in shaping the future of orthodontic and dental treatment solutions.
Investing in Align Technology, Inc. (ALGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Align Technology, Inc. stock to fluctuate between $122 (low) and $237.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-01-12, Align Technology, Inc.'s market cap is $12,341,211,732, based on 71,751,231 outstanding shares.
Compared to Eli Lilly & Co., Align Technology, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Align Technology, Inc. (ALGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALGN. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Revenue: $3,999,012,000 | EPS: $5.63 | Growth: -3.26%.
Visit https://www.aligntech.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $737.45 (2021-09-23) | All-time low: $122 (2025-09-25).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

businesswire.com
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (2:0.

zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com
Align Technology's Thailand debut of Invisalign with MAOB lifts shares and expands its Class II treatment options for increasing patients.

businesswire.com
BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced commercial availability in Thailand of the Invisalign System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and dental correction by.

seekingalpha.com
Align Technology, Inc. (ALGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

seekingalpha.com
Align Technology, Inc. (ALGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

zacks.com
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock?

zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

businesswire.com
MANILA, Philippines--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced commercial availability in the Philippines of the Invisalign System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and d.
See all news